Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
